List of investigational sexual dysfunction drugs explained
This is a list of investigational sexual dysfunction drugs, or drugs that are currently under development for clinical treatment of sexual dysfunction but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Atrophic vaginitis
Erectile dysfunction
Female anorgasmia
Female sexual dysfunction
- BP-101 – undefined mechanism of action (BP 101 - Ovoca Bio - AdisInsight)
- Bupropion/trazodone (S1P-104, S1P-205, Lorexys, Orexa) – norepinephrine reuptake inhibitor, nicotinic acetylcholine receptor antagonist, 5-HT2A receptor antagonist, α1-adrenergic receptor antagonist, weak serotonin reuptake inhibitor (Bupropion/trazodone - AdisInsight)
- Buspirone/testosterone (Lybridos) – 5-HT1A receptor partial agonist and androgen receptor agonist (Buspirone/testosterone - Emotional Brain - AdisInsight)
- Lasofoxifene (CP-336156, CP-336156-CB, Fablyn, Oporia) – selective estrogen receptor modulator (Lasofoxifene - Sermonix Pharmaceuticals - AdisInsight)
- PL-6983 – selective MC4 receptor agonist (Research programme: sexual dysfunction therapy - Palatin Technologies - AdisInsight)
- Sildenafil/testosterone (Lybrido) – PDE5 inhibitor and androgen receptor agonist (Sildenafil/testosterone - Emotional Brain - AdisInsight)
- TGFK09SD – 5-HT1A receptor agonist (TGFK 09SD - AdisInsight)
Premature ejaculation
Unspecified
See also
External links